https://investor.lilly.com/news-releases/news-release-details/lilly-spotlight-growing-hematology-portfolio-2026-european investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lillys-retevmo-selpercatinib-demonstrated-83-reduction-risk investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-mounjaro-and-retatrutide investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/foundayo-and-zepbound-now-covered-millions-americans investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lilly-participate-goldman-sachs-47th-annual-global-healthcare investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88 investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/foundayo-orforglipron-once-daily-pill-taken-without-food-or investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lilly-showcase-oncology-portfolio-across-tumor-types-and investor.lilly.com
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss investor.lilly.com
